MARKET

AIM

AIM

Aim Immunotech
AMEX
0.1345
+0.0055
+4.26%
Opening 10:27 02/18 EST
OPEN
0.1320
PREV CLOSE
0.1290
HIGH
0.1378
LOW
0.1303
VOLUME
335.99K
TURNOVER
--
52 WEEK HIGH
0.6200
52 WEEK LOW
0.1202
MARKET CAP
9.25M
P/E (TTM)
-0.2839
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AIM last week (0210-0214)?
Weekly Report · 1d ago
AIM ImmunoTech to not proceed with offering pursuant to registration statement
TipRanks · 02/11 13:45
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
Barchart · 02/11 07:45
Weekly Report: what happened at AIM last week (0203-0207)?
Weekly Report · 02/10 10:20
AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist
TipRanks · 02/07 13:56
AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2
TipRanks · 02/05 13:26
Weekly Report: what happened at AIM last week (0127-0131)?
Weekly Report · 02/03 10:22
Weekly Report: what happened at AIM last week (0120-0124)?
Weekly Report · 01/27 10:24
More
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Webull offers AIM ImmunoTech Inc stock information, including AMEX: AIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AIM stock methods without spending real money on the virtual paper trading platform.